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Today, there are conflicting data on the content of cancer stem cells responsible for recurrence and resistance to chemotherapy 
in tumors of human brain. The aim of the study was to analyze the content of CD133+ cells in different brain tumors by immunofluo-
rescence assay and immunohistochemical method. Materials and Methods: The samples of different brain tumors removed during 
neurosurgical operations were studied for CD133 expression. Results: Immunofluorescence assay of tumor imprints revealed CD133+ 
cells in 40–85% of tumors regardless of histological type. In malignant tumors, the count of CD133+ cells was higher than in benign 
tumors. Immunohistochemical method used for detection of CD133+ cells was less sensitive than immunofluorescence technique. 
The number of CD133+ cells may vary even in tumors of the same histological type. In 20–30% of malignant tumors (glioblastomas, 
medulloblastomas), the content of CD133+ cells was very low or not detected at all. Conclusions: In tumors of the brain of different 
genesis and degree of anaplasia CD133+ cells are found out. In malignant tumors (glioblastomas and medulloblastomas), CD133+ 
cells are much more frequently detected than in benign brain tumors. The content of CD133+ cells in brain tumors is highly variable 
being small and some malignant tumors, indicating low predictive and diagnostic value of cancer stem cell content in clinical practice.
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Presently a special attention of many researchers 
is focused on the study of tumor cells that have the 
properties of stem cells. It is believed that this area 
of research will provide a new understanding of the 
nature of cancer, the causes of inefficiency of various 
methods of its treatment, and will contribute to the 
development of the effective therapeutic approaches.
One of the first evidences on the existence of stem 
cell tumor cells (STCs) was found by Bonnet and Dick 
in 1997. They investigated acute myeloid leukemia, 
in which a subpopulation of 0.01–1% of the total popu-
lation of cells phenotypically characterized as CD34+ 
could cause leukemia after transplantation to immu-
nodeficient mice [1].
The data obtained in recent years have shown 
the presence of STCs in tumors of the colon, breast, 
pancreas, liver, lung and brain (gliomas, medulloblas-
tomas, ependymomas, etc.) [2–5]. Until recently it was 
assumed that the STCs counts in a number of malig-
nancies yield up to 0.01–1% of the total population 
of tumor cells, but presently it is supposed that the 
number of STCs in various tumor types ranges from 
1 to 20%, and in some cases is even higher. STCs of the 
brain tumors are characterized by unlimited capacity for 
self-renewal, the formation of tumors in experimental 
immunodeficient mouse, genetic damage and the 
generation of new tumor cells [6]. STCs have high abil-
ity to invade, stimulate the formation of blood vessels 
and promote cell migration [2, 3]. They are also involved 
in the carcinogenesis, and there is growing evidence 
that these cells contribute to tumor progression [7] and 
metastasis [8]. This type of cells is responsible for resis-
tance of tumors to chemo- and radiotherapy, recurrence 
after surgical intervention and radiation therapy. There 
remains a disputable issue regarding the origin of STCs. 
Neuronal stem cells (NSCs), neuronal cells, precursors 
and differentiated glioma cells are considered as the 
sources of STCs. Shiras et al. confirmed the possibility 
of the spontaneous transformation of CD133+ normal 
stem cells to STCs with a potential to produce invasive 
brain tumors in immunodeficient mice [9]. Junier and 
Sharif [10] demonstrated that after exposure to trans-
forming growth factor (TGF-α), which is expressed 
at the early stages of tumor progression, astrocytes 
can acquire the phenotype of neuronal precursor cells 
becoming malignant after irradiation. This indicates the 
possibility of malignant transformation in mature glial 
cells and the formation of gliomas [11].
Several methods of obtaining and identifying the ce-
rebral STCs are now described including the expression 
of the CD133 (prominin-1) molecule; the identification 
of the “side population” (SP); the formation of the neuro-
spheres in cell culture in vitro and the ability of STCs to re-
produce the tumor histologically identical to the primary 
tumor in immunodeficient animals. The most commonly 
used method is the determination of CD133 molecule 
(prominin-1) as a marker for many STCs identified to date 
in the tumors of brain, lung, liver, prostate, etc. [4, 12]. 
Using a flow cytofluoro metry, it is possible to isolate 
STCs by positive expression of CD133. With the use 
of flow cytofluorometry it was demonstrated [13] that 
the content of CD133+ cells in glioblastomas ranged from 
0.1 to 46.8%, in medulloblastomas from 6.1 to 45.4%, 
and pilocytic astrocytomas from 3.5 to 37.1%. In an-
other study [14] using immunohistochemical approach 
the high (more than 60%) content of CD133+ cells was 
shown in tumor tissue. Data on the prognostic value 
and correlation between the level of CD133+ cells and 
the survival time of patients with gliomas are contradic-
tory. Pallini et al. demonstrated that the increased count 
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of CD133+ cells and CD133/Ki-67 co-expression were 
associated with poor survival in patients with glioblas-
toma [15]. Zeppernick et al. [16] found that the pres-
ence of CD133 clusters and large amounts of CD133+ 
cells correlated with a short survival period. However, 
Kim et al. did not establish the dependence between 
the level of CD133+ cells and the survival of patients with 
glioblastoma multiforme [17, 18].
Another technique for STC analysis consists in de-
lineation of SP based on the ability of STC for the efflux 
of fluorescent dyes in vitro due to the activity of ABC 
transporters.
It should be noted that until now, the panel of specific 
markers of the STC has not been clarified. It is shown 
that stem cells isolated from gliomas express such 
markers as CD133, CD105, CD90, CD15, CD24, CD20, 
CD44, Nanog, Oct3/4, CXCR4 (CD184), NF (neurofila-
ment protein), GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase). In addition, STCs express the markers 
characteristic for the NSC, such as GFAP (glial fibrillary 
acid protein), Nestin, Sox-2, Musashi-1, Bmi-1 and 
do not express the early (Tuj1) and late (NeyN) neuro-
nal markers and oligodendroglial marker Olig-1 [19]. 
Antigen CD15, which is identified in normal tissues and 
in different types of cancers, including gliomas [20] 
is regarded as a marker of STC. Implantation of CD15+ 
cells from the glioma into the brain of a mouse causes 
the formation of new tumors [21]. According to the liter-
ature, there are significant differences in the frequency 
and number of STCs in tumors depending on different 
methods of their determination.
The aim of our study was to determine STC content 
in different brain tumors using immunohistochemical 
and immunofluorescence techniques.
MATERIALS AND METHODS
Patients. The biopsies of intracerebral tumors 
of various histological types obtained during neuro-
surgery operations performed at Romodanov Neu-
rosurgery Institute (Kyiv, Ukraine) were used. The ex-
periments were done in accordance with the bioethics 
regulations and under permission of Bioethics Com-
mission of RNI. In all cases, a written informed consent 
was obtained from the patients. Histological diagnosis 
of brain tumors was done according to the latest WHO 
classification of tumors of the CNS (2007) [22].
Immunocytofluorescence detection of CD133 
in the imprints-smears of brain tumor samples was 
performed by a standard method using specific prima-
ry anti-CD133 antibodies (clone 17A6.1) from Millipore 
(USA) in a working dilution of 1:100. Anti mouse-FITC 
labeled antibodies (Labdiagnostika, Russia) were used 
as secondary antibodies. The samples were examined 
using fluorescence microscope Zeiss (Germany) with 
wide-band and narrow-band filters.
Immunohistochemical study. For an immuno-
histochemical study, histological sections of tumor 
samples as well as imprints were used. The specimens 
were routinely processed according to the instructions 
of the manufacturer (Thermo scientific, UK). The pri-
mary anti-CD133 antibodies (clone 17A6.1) of Millipore, 
(USA) were used in a working dilution of 1:100. For 
immunostaining, HRP Polymer Qundit, DAB Substract 
Quonto and DAB Chromogen Quonto (Sigma, Ger-
many) were used. After development of the reaction, 
the slides were counterstained with methyl green.
Statistical analysis. The software package Statis-
tica 6.0 was used. Statistical analysis was performed 
with Pearson χ2 test. A difference between means was 
considered significant if p value was less than 0.05.
RESULTS AND DISCUSSION
Immunofluorescent detection of CD133 expres-
sion on the surface of cells of CNS tumors of different 
histological type and degree of malignancy has shown 
the substantial differences, in particular in the inten-
sity and nature of specific fluorescence. The results 
of immunofluorescent analysis of tumor imprints are 
shown in Fig. 1. Differences were also found in the 
morphological features of the cells Namely, CD133+ 
cells were smaller compared to other cells of the test 
tumor sample. We found that the percentage of CD133+ 
samples was higher in malignant tumors (glioblastoma, 
medulloblastoma, anaplastic astrocytoma) than in be-
nign ones (Table 1).
Fig. 1. Immunofluorescent analysis of CD133 expression using 
a narrow-band filter and FITC labeled antibodies. CD133+ cells 
glow brightly in light color; CD133− cells are dull green, × 400. 
a — medulloblastoma; b — glioblastoma
Table 1. Frequency of detection of CD133+ cells in human brain tumors
Histological type CD133
+ cases
Number of cases %
Glioblastoma (n = 20) 15 75.0
Anaplastic astrocytoma (n = 8) 8 100.0
Fibrillary-protoplasmic astrocytoma (n = 18) 11 61.1
Medulloblastoma (n = 7) 6 85.7
Primitive neuroectodermal tumors (n = 3) 0 0.0
Other types of benign tumors (n = 10) 4 40.0
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Although some researchers argue that the rate 
of detection of CD133+ cells does not correlate with 
tumor malignancy, it is definitely well known that 
CD133+ STCs possess higher (4–5-fold) invasive 
capacity compared to non-stem tumor cells both 
in vitro and in vivo [23]. Accordingly, an increase in the 
number of cells in this subpopulation contributes not 
only to tumor angiogenesis but also to metastasis. 
Our data show that in malignant tumors STCs are 
detected more frequently, and the tumors of the 
same histological type had a different quantitative 
composition of the CD133+ cell subpopulations. 
Also, in samples from malignant tumors, especially 
in malignant tumors with a high level of anaplasia such 
as glioblastoma, meningioma and anaplastic astrocy-
toma, CD133+ cells are more abundant than in benign 
tumors (Table 2). The increase in the number of STCs 
may reflect their increased proliferation and genetic 
reprogramming of more differentiated glioma cells 
toward the “stem” phenotype with accompanying 
increase in the expression of the “stem” markers 
OCT-4, NANOG, c-MYC, responsible for maintain-
ing the pluripotent properties of the STC [24–26]. 
It is known that CD133+ cells isolated from neuronal 
human tumors are tumor cells that undergo various 
stages of both neuronal and astrocyte differentiation 
[5, 6]. Consequently, the presence of a large number 
of CD133+ cells may indicate an active tumor progres-
sion, and therefore may be consi dered as an indicator 
of unfavorable prognosis.
Table 2. Distribution of CD133+ scores in samples of human brain tumors 
of various histological type
Histological type
Number and percentage (in brackets) 
of samples with different scores  
of CD133-immunopositivity
± + ++ +++
Glioblastoma (n = 15) 5 (33.3) 4 (26.7) 5 (33.3) 1 (6.7)
Anaplastic astrocytoma 
(n = 8) 2 (25.0) 5 (62.5) 1 (12.5) —
Fibrillary-protoplasmic as-
trocytoma (n = 11) 6 (54.6) 5 (45.4) — —
Medulloblastoma (n = 6) 1 (16.7) 3 (50.0) 1 (16.7) 1 (16.7)
Other types of benign tu-
mors (n = 4) 3 (75.0) 1 (25.0) — —
Note: ± — 1–2 cells per field; + — 3–5 cells per field; ++ — 10–15 cells per 
field; +++ — 20–30 cells per field.
Using immunohistochemical technique we have 
analyzed CD133 expression in the following groups 
of brain tumor samples: 1) 44 samples of medul-
loblastoma from adult patients; 2) 20 samples 
of medulloblastoma from children aged 1 to 12 years; 
3) 21 samples of glioblastoma; and 4) 5 primitive 
neuroectodermal tumors (Fig. 2). The distribution 
of CD133+ samples within each group is shown 
in Table 3.
Fig. 2. Immunohistochemical staining of CD133+ cells in samples of various brain tumors. Counterstaining with methylene green, 
x 400. a — non-uniform distribution (focal accumulation) of CD133+ cells in the tissue of medulloblastoma from an adult patient; 
b — distal and superior distribution of CD133+ cells in glioblastoma; c — single CD133+ cells in the area of invasive growth of glio-
blastoma; d — single CD133+ cells in the primitive neuroectodermal tumor
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Table 3. The frequency of detection of CD133+ cells in different tumor types
Groups of patients
Number of CD133+ samples  
to the total number of samples  
(percentage in brackets)
Group 1 (adult patients with medullo-
blastoma, n = 44)
30/44 (68.18)
χ21–2 = 1.99, р = 0.26
Group 2 (children with medulloblasto-
ma, n = 20) 17/20 (85.00)
Group 3 (glioblastoma, n = 21) 19/21 (90.47)
χ21–3 = 1.64, р = 0.19
Group 4 (primitive neuroectodermal 
tumors, n = 5)
3/5 (60.00)
χ21–4 = 0.2, р = 0.83
According to data of Table 3, 85–90% of the total 
number of studied histological samples of glioblastomas 
and medulloblastomas in children are CD133+ which 
coincides with the known literature data reporting the 
presence of CD133 cells in > 80% of samples of glio-
blastomas. In adult medulloblastomas, the number 
of tumors with CD133+ cells was lower (68.13%), although 
there was no statistically significant difference between 
adult and pediatric medulloblastomas (р > 0.05). But 
analysis of the distribution of CD133-positivity scores 
in these groups demonstrated the significant differences 
(Table 4). Thus, among adults with medulloblasomas, 
the samples with a low count of CD133+ cells were found 
more often than in childhood medulloblastomas. When 
compared with glioblastomas, it was found that in adult 
medulloblastomas, the number of samples with low STC 
counts was 6-fold higher than in glioblastomas. At the 
same time, the percentage of tumors with high content 
of STC in medulloblastomas from adults and children was 
approximately the same and amounted to 23% contrast-
ing to more than 50% in glioblastomas.
Table 4. Distribution of CD133-positivity scores in brain tumors of various 
histological type
Groups of patients
Total 
number 
of CD133+ 
tumors
CD133-positivity scores, %
1 2 3
Adult patients with me-
dulloblastoma (n = 30) 30
30.00  
(n = 9)
χ21-2 = 0.34
р = 0.5
46.67  
(n = 14)
23.33  
(n = 7)
χ21-2 = 0.23
р = 0.73
Children with medullo-
blastoma (n = 17) 17
5.89  
(n = 1)
70.58  
(n = 12)
23.53  
(n = 4)
Glioblastoma (n = 19)
19
5.26*  
(n = 1)
χ21-3 = 4.2
р = 0.038
36.84  
(n = 7)
57.89%*  
(n = 11)
χ21-3 = 4.5
р = 0.032
Note: *The differences are significant compared to the group with adult me-
dulloblastomas (p < 0.05).
Analyzing the data on the frequency and extension 
of tumor infiltration with STC one could conclude that 
intracerebral malignant tumors contain different amounts 
of these cells. In adult medulloblastomas, about one third 
of samples does not contain STCs, and the other third 
contains only a small amount of CD133+ cells. The per-
centage of such tumors with low content of STC among 
adult medulloblastomas is twice higher than in childhood 
medulloblastomas and six times higher than in glioblas-
tomas. Such patterns of CD133-positivity may reflect 
some biological differences between glioblastomas and 
childhood medulloblastomas, namely, fewer CD133+ cell 
counts in these tumors may indicate a lower proliferation 
rate of cancer cells and slow-down of tumor growth that 
leads to clinical manifestations of these tumors later 
in life and the easier course of the disease in adults than 
in children, according to numerous literature data. One 
should mention that other factors, such as particular 
genetic changes, viral, and environmental carcinogens 
along with the STCs play a role in the development 
of medulloblastomas. This suggests that the larger STC 
count in glioblastoma as well as medulloblastoma is not 
entirely typical feature for these tumors.
The frequency of detection and the patterns of score 
distribution of STCs in the tumor samples largely de-
pend on the method used in the study. We have shown 
that the immunofluorescence is more accurate and sen-
sitive than immunohistochemical technuique. More im-
portant in our study is the fact of STC detection in benign 
tumors. This calls into question the hypothesis that STCs 
are characteristic only for malignant tumors but not for 
benign ones. On the other hand, even in tumors of the 
same histological type, for example medulloblastomas 
or glioblastomas, a significant percentage of samples 
lacks STCs. There is no reasonable explanation in the 
latter observation, which indicates both the need for 
further research of this problem and low predictive and 
diagnostic value of the STC content in clinical practice.
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